ANTIBODY MOLECULE HAVING SPECIFICITY FOR HUMAN TUMOR NECROSIS FACTOR ALPHA AND USE THEREOF

• Main Authors: BROWN DEREK T, CHAPMAN ANDREW P, CHARLES WEIR ANDREW NEIL, POPPLEWELL ANDREW G, KING DAVID J, ATHWAL DILJEET S
• Format: Patent
• Language: English
• Published: 06.08.2009
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide an antibody molecule having specificity for an antigenic determinant group of human tumor necrosis factor (TNF α), and to provide a therapeutic use of the antibody molecule and a method for producing the antibody molecule. SOLUTION: The antibody molecule containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF α is disclosed. The CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR is disclosed. The DNA sequence encoding the chain of the antibody molecule, vector, transformed host cell and uses of the antibody molecule in the treatment of diseases mediated by TNF α are disclosed. COPYRIGHT: (C)2009,JPO&INPIT